MDGL Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -143.55%. Madrigal Pharmaceuticals's return on equity of -49.57% beat BridgeBio Pharma's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 73.69%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 50.18x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -10220.14%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Cytokinetics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 136.94%. Given that Cytokinetics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Cytokinetics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Cytokinetics quarterly revenues of $1.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than Cytokinetics's net income of -$161.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 186.93x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of 40.56%. Madrigal Pharmaceuticals's return on equity of -49.57% beat United Therapeutics's return on equity of 19.92%.

Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 27.13%. Given that Madrigal Pharmaceuticals has higher upside potential than United Therapeutics, analysts believe Madrigal Pharmaceuticals is more attractive than United Therapeutics.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than United Therapeutics's net income of $322.2M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 4.92x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -49.57% beat Viking Therapeutics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 229.43%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.